Effects of the Supplementation of N-acetylcysteine on Redox Imbalance, Cytokine Levels, and Perinatal Outcomes in Pregnant Women with Preeclampsia: A Double-Blind, Randomized, Placebo-Controlled Pilot Study
Background/Objectives: This study aimed to evaluate the effects of oral administration of N-acetylcysteine (NAC) in pregnant women with preeclampsia (PE), using serum markers of redox imbalance and cytokine levels and perinatal outcomes. Methods: A double-blind, randomized, placebo-controlled pilot study was carried out from 2021 to 2023. The study was retrospectively registered with REBEC (Brazilian Clinical Trials Registry). After screening, women were randomized into 2 groups according to the type of supplementation: 600 mg of NAC (NAC group) or capsules containing 2% colloidal silicon dioxide and 98% microcrystalline cellulose (placebo group) until delivery. Blood samples were collected to quantify biomarkers of redox imbalance and cytokine levels. Questionnaires containing socioeconomic, clinical, obstetric, and anthropometric data were applied. Results: A total of 51 pregnant women with PE were included (26 in the placebo group and 25 in the NAC group). The use of NAC was associated with a higher gestational age at birth (GA) of the conceptus (placebo group: 37.39 weeks ± 1.96 SD vs. NAC group: 38.45 weeks ± 1.51 SD; p = 0.044). A moderate effect size was observed for this variable (Cohen’s d = 0.52). However, treatment allocation (NAC vs. control) was not independently associated with gestational age at birth after adjustment for covariates (F(1,28) = 0.144; p = 0.707; η2p = 0.005). The adjusted mean difference between groups was 0.92 weeks (95% CI: −0.16 to 2.00). No other significant effects on redox and inflammatory markers were identified using NAC. Conclusions: NAC supplementation did not impact the mode of delivery between the NAC and placebo groups. As a secondary exploratory finding, a possible trend toward prolonged gestational age was observed in the NAC group; however, this result should be interpreted with caution, given the exploratory nature of the analysis, the neutrality of the primary outcome, and the limited sample size.
Authors
- Alexandra Rodrigues Bezerra (ORCID: https://orcid.org/0000-0002-4179-5917)
- Marília Oliveira Fonseca Goulart (ORCID: https://orcid.org/0000-0001-9860-3667)
- Marilene Brandão Tenório Fragoso (ORCID: https://orcid.org/0000-0002-7504-0491)
- Tauane Alves Dutra (ORCID: https://orcid.org/0000-0001-5236-9318)
- Fabiana Andréa Moura (ORCID: https://orcid.org/0000-0003-0625-0193)
- Micaely Cristina dos Santos Tenório (ORCID: https://orcid.org/0000-0002-1771-489X)
- Nassib Bezerra Bueno (ORCID: https://orcid.org/0000-0002-3286-0297)
- Orlando Roberto Pimentel de Araújo (ORCID: https://orcid.org/0000-0003-4189-6520)
- Nathálya da Silva Severino
- Alane Cabral Menezes de Oliveira (ORCID: https://orcid.org/0000-0002-7497-919X)
- Amylly Sanuelly da Paz Martins (ORCID: https://orcid.org/0000-0002-3011-1145)
- Bianca Gomes de Gomes de Souza (ORCID: https://orcid.org/0000-0002-5366-181X)
- Danielle Alice Vieira da Silva
Institutions
- Instituto Federal de Educação, Ciência e Tecnologia de Alagoas (BR)
- Universidade Federal de Alagoas (BR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-08-25
- DOI
- https://doi.org/10.3390/ph19091344
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico